Authors
Latest:
Future of HER2-Directed Tumor-Agnostic TherapiesPanelist discusses how HER2-directed tumor-agnostic treatments are likely to see expanded applications across multiple cancer types, driven by improved biomarker testing and emerging clinical evidence. This approach may become increasingly personalized through enhanced molecular profiling, potentially leading to more precise patient selection and combination strategies.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy ResponseCancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.
Latest:
Metastatic Renal Cell Carcinoma With Sarcomatoid FeaturesIn this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.
Latest:
Knowledge, Understanding are Key to Mitigating RCC Treatment DisparitiesIt is important not to wash over the disparities in treatment access for renal cell carcinoma as merely another statistic and take action on guiding patients to treatment, says Solomon Woldu, MD.
Latest:
Unmet Needs and Future Perspectives in Multiple MyelomaA panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.
Latest:
Standard HER2 Assays Do Not Accurately Identify HER2-Low Breast CancerData collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.
Latest:
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research RecommendationsThis review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate CancerAblative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Latest:
Future Directions in Graft vs Host Disease ManagementClosing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.
Latest:
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing PracticeRegistered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Latest:
PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal MetsFuture research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Latest:
Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular LymphomaExpert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.
Latest:
Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community CenterPanelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.
Latest:
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and ComorbiditiesIn this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Kami J. Maddocks, MD, Shows Optimism for Future Development of Cellular Therapies in LymphomaIn an interview, Kami J. Maddocks, MD, details therapies that may shake up the standard of care in lymphoma going forward.
